Lawsuits for Uterine Cancer Spread Following Laparoscopic Myomectomy with Morcellation
The product liability lawyers at Saiontz & Kirk, P.A. are reviewing potential claims for women diagnosed with the spread of cancer following a laparoscopic myomectomy where a power morcellator was used for surgical removal of uterine fibroids.
In recent years, power morcellators have been used during many laparoscopic or robotic myomectomy procedures to allow doctors to cut the uterine fibroids into small pieces that may be removed through an incision in the abdomen. However, use of these devices may cause unsuspected sarcoma to be spread throughout the body, resulting in a diagnosis of:
- Leiomyosarcoma (LMS)
- Endometrial Stromal Sarcoma (ESS)
- Other Cancer Diagnosed Following Uterine Fibroid Surgery
Financial compensation may be available through a myomectomy cancer lawsuit as a result of the manufacturers’ failure to provide adequate warnings about the risks associated with power morcellation for uterine fibroid removal.
To review a potential case for yourself or a loved one, request a free consultation and claim evaluation.
Myomectomy Morcellation Cancer Risks
Unlike a hysterectomy, during which the entire uterus is removed, a myomectomy involves the removal of uterine fibroids and the reconstruction of the uterus, so that it remains functional and fertility is hopefully retained.
Power morcellators are medical devices introduced by several different manufacturers to allow surgeons to perform a minimally invasive myomectomy, resulting in a smaller scar, less recovery time and reduced risk of infection or other complications.
Amid emerging concerns within the medical community, the FDA warned doctors in April 2014 to avoid using power morcellators during myomectomy procedures due to the risk of upstaging undiagnosed cancer.
The agency estimated that about 1 out of every 350 women who undergo uterine fibroid removal may have unsuspected sarcoma or leiomyosarcoma, with no reliable way for doctors to diagnose the cancer before a power morcellator is used.
Morcellation during a myomectomy may cause this cancerous tissue to be spread throughout the abdomen, greatly reducing a woman’s chances for long-term survival with the uterine cancer.
While many critics have called for a power morcellator recall to be issued, removing the devices from the market entirely, the FDA has kept the devices on the market with stronger warnings announced in November 2014.
Due to the myomectomy cancer risks, most experts agree that power morcellators should not be used in the vast majority of all uterine fibroid removal surgeries.
Laparascopic or Robotic Myomectomy Lawsuits
The myomectomy cancer lawyers at Saiontz & Kirk, P.A. are reviewing potential claims for women and families throughout the United States who have been diagnosed with leiomyosarcoma, endometrial stromal sarcoma or other uterine cancer that may have been spread by the use of a power morcellator during:
- Laparoscopic Myomectomy
- Robotic Myomectomy
Potential hysterectomy morcellation lawsuits are also being reviewed for women diagnosed with cancer disseminated following surgical removal of the entire uterus.
It appears that the manufacturers of these dangerous medical devices knew or should have known risks associated with uterine fibroid morcellation, yet information was withheld from consumers or the medical community.
All cases are reviewed by Saiontz & Kirk, P.A. under a contingency fee agreement, which means that there are never any out-of-pocket costs to hire our law firm and we receive no attorney fees or reimbursed expenses unless a recovery is obtained for cancer spread during a myomectomy or uterine fibroid removal.